EYPT

EyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating.

Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.

EyePoint announced that LUCIA, its second Phase 3 clinical trial of DURAVYU for wet AMD treatment, failed to meet its primary endpoint of non-inferiority in visual acuity versus aflibercept control. However, the drug demonstrated visual improvement and met key secondary endpoints including a 38% reduction in treatment burden and strong anatomic control. The company plans to conduct additional analyses and remains focused on its Phase 3 DME program with data expected in Q4 2027.